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Editorial 
 
Challenges and counter challenges in HIV/AIDS 
 
Qingsheng Li and Charles Wood 
 
ince the beginning of the HIV/AIDS pandemic, there 
has been significant progress in combating the virus. 
In addition to identifying HIV,1 scientists have developed 
an array of antiretroviral drugs and successfully 
converted the once deadly disease into a treatable and 
chronic condition.2 Nevertheless, this battle is far from 
over and HIV still outsmarts humans in multiple ways 
and poses tremendous challenges. Within this context, the 
Chinese Medical Journal has timely published this 
special issue on HIV/AIDS, highlighting the ongoing 
challenges posed by HIV and potential solutions to these 
problems. 
 
The most daunting challenge is to develop prophylactic 
measures such as vaccines and microbicides to prevent 
HIV transmission. HIV vaccine development has been 
dominated by a theme of frustration and failure, best 
exemplified by the futility of the Merck Ad5 phase IIb 
T-cell vaccine.3 Recently for the first time in the history 
of HIV vaccine efficacy trials, human RV144 Thai trial 
revealed a modest but significant improvement in efficacy 
against HIV transmission.4 However, researchers still 
have yet to identify the immune correlates of 
RV144-vaccine-induced-protection or to find the best 
way to design HIV vaccine post-RV144 to enhance 
modest protection to a level that is practical for clinical 
use. Recent reconstruction of an exceptionally broadly 
neutralizing antibody-VRC015,6 using novel approaches 
may open a new avenue for better understanding and 
design of immunogenic antigen to elicit broadly 
neutralizing antibodies through vaccination.  
 
Dr. Wan and colleagues7 on page 3489 of this issue 
reviewed the current state of HIV-1 vaccine development 
encompassing the present understanding of the basic 
biology of newly transmitted virus, tailoring innate 
immune response through toll-like receptors and dendritic 
cells to elicit protective adaptive immunity, especially at 
the mucosal site of viral entry. Of note, this review also 
covered the important issues of immunogenicity, new 
adjuvants and replication competent vectors, and the state 
of AIDS vaccine clinical trials in China.    
 
Similar to the difficulties in developing an HIV vaccine, 
HIV microbicides have also faced numerous unsuccessful 
efficacy trials except for the recent CAPRISA 004 trial. 
The 004 trial demonstrated a reduction of HIV acquisition 
by an estimated 39% overall and by 54% in women with 
high gel adherence using 1% vaginal gel formulation of 
tenofovir, a nucleotide reverse transcriptase inhibitor.8 
Many of topical microbicide candidates advanced into 
clinical trials have failed, such as nonooxynol-9, because 
they can cause mucosal inflammation and damage.9 Thus 
identification of mucosal inflammatory biomarkers to 
evaluate the mucosal toxicity of candidate microbicides is 
urgently needed. Dr. Li and his colleagues10 on page 3381 
assessed the cytokine profiles in mouse vaginal secretion 
and histopathological changes in cervicovaginal mucosa 
after vaginal exposure to Nonooxynol-9. They found that 
interleukin-17A (IL-17A), IL-6, IL-4 and IL-10 are 
significantly correlated with mucosal damage caused by 
nonooxynol-9. This study indicates that profiling of 
cytokines in vaginal secretion may be a useful tool to 
predict the mucosal toxicity induced by candidate 
microbicides. 
 
Some other challenges in the HIV/AIDS research field 
are treatment related, such as drug resistance, 
complications associated with anti-retroviral therapy 
(ART), and treatment management in persons with 
opportunistic infections or other pathogen coinfection.   
 
HIV drug resistance can be acquired through transmission 
and/or post transmission during ART, jeopardizing the 
success of ART. Detecting and monitoring of 
drug-resistant virus is of importance for treatment 
management at individual and population levels.11 Since 
developing countries use different and limited ART drugs 
from developed countries, drug resistance data from 
foreign registries are not directly applicable. 
 
Dr. Guo and his colleagues12 on page 3389 reported the 
detection of the most common non-nucleoside reverse 
transcriptase inhibitor (NNRTI) or nucleoside reverse 
transcriptase inhibitor (NRTI) drug resistant mutations in 
Chinese HIV+ individuals using allele-specific real-time 
PCR and found this method to be much more sensitive 
than bulk sequencing. This method can now be used to 
monitor drug resistance in HIV infected individuals in 
China.   
 
Dr. Zeng and his colleagues13 on page 3396 in this issue 
measured arterial stiffness using pulse wave velocity 
(PWV) analyses in Chinese HIV+ individuals. They found 
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that HIV+ individuals not receiving ART have 
significantly higher PWV than that of HIV− individuals, 
indicating that HIV infection may increase arterial wall 
stiffness; HIV+ individuals receiving ART (only NNRTI 
or NRTI) have significantly lower PWV than that of HIV+ 
individuals not receiving ART.  
 
Dr. Zhang and his colleagues14 on page 3400 conducted a 
retrospective cross-sectional study on pulmonary 
tuberculosis in HIV+ individuals and found that 4.4% of 
Chinese HIV+ individuals (CD+ <350 cells/µl) were 
coinfected with pulmonary tuberculosis.   
 
While the conclusions of the above three studies need to 
be validated in a more powered and longitudinal studies, 
the results of these studies are informative.  
   
HIV R144 vaccine trial provides us optimism for 
countering the challenges posed by HIV/AIDS; 
nonetheless there is still a long fight ahead against this 
versatile virus. This special issue on HIV/AIDS is just 
another step of this long journey to the ultimate defeat of 
HIV.  
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